When Johnson & Johnson (NYSE:JNJ) highlighted 12 potential blockbusters from its pipeline in May there were a few on the list that raised eyebrows. Two of these - the flu project pimodivir and the respiratory syncytial virus candidate lumicitabine - are in a sector where the company is not currently well known: infectious diseases.
"It's a new area to J&J to a certain extent," Julian Symons, head of Janssen's respiratory infections division, tells EP Vantage. "But it's a huge unmet medical need, and all our medicines are first-in-class agents." J&J still has a long way to go, however, before it can show that these assets live up to its lofty expectations.
READ FULL ARTICLE HERE